SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!
风吹紫檀香
Lv3
270 积分
2023-07-06 加入
最近求助
最近应助
互助留言
AACR-NCI-EORTC - 34th International Symposium on Molecular Targets and Cancer Therapeutics. Barcelona - October 26-28, 2022
6天前
已完结
EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer
10个月前
已关闭
Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification
10个月前
已完结
Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis
10个月前
已完结
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
11个月前
已完结
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
11个月前
已完结
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
1年前
已完结
A phase I study of the Wee1 kinase inhibitor adavosertib (AZD1775) in combination with chemoradiation in cervical, upper vaginal, and uterine cancers
1年前
已完结
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
1年前
已完结
[Chinese guideline for diagnosis and management of drug-induced liver injury (2023 version)]
1年前
已完结
没有进行任何应助
点赞,速度真快,帮大忙了,么么哒
6天前
帮大忙了
10个月前
非常感谢
1年前
速度真快,帮大忙了,么么哒
1年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论